Buda Juice (BUDA) Q4 2025 earnings review
Top-Line Success Masking Severe Q4 Profitability Deceleration
Buda Juice achieved an 11.8% increase in FY25 revenue, proving demand for its Ultra Fresh category. However, the top-line narrative obscures a reversing profitability trend. While full-year Adjusted EBITDA grew slightly to $3.8M, Q4 performance was alarming: Net Income plunged 30% YoY, and Adjusted EBITDA margins collapsed from 33.4% to 24.8%. The company points to a successful January 2026 IPO to fund growth, but surging SG&A costs are currently stripping away the operating leverage needed to make that growth profitable.
🐂 Bull Case
Double-digit FY25 revenue growth ($12.6M) validates the Ultra Fresh proposition in the supermarket fresh perimeter, successfully replacing shelf-stable alternatives.
The January 2026 IPO provides a massive capital injection compared to the meager $1.8M cash balance at year-end, enabling the company to scale its proprietary cold-chain infrastructure nationally.
🐻 Bear Case
Despite annual growth, Q4 Adjusted EBITDA fell 22% YoY to $0.7M. The 860 basis point contraction in Q4 EBITDA margin suggests serious unit economic degradation heading into FY26.
SG&A expenses surged 28.8% YoY to $1.67M, growing nearly three times faster than revenue. This operational bloat completely erased any gross profit gains from increased volume.
⚖️ Verdict: 🔴
Bearish. Management is highlighting full-year double-digit growth, but backing into Q4 metrics reveals severe margin compression and decelerating momentum just before they tapped public markets.
Key Themes
Hidden Q4 Revenue Deceleration
Management boasts about 'double-digit revenue growth' for the year, but the Q4 reconciliation tables tell a contradicting story. Based on the reported Q4 Adjusted EBITDA of $0.7M and a 24.8% margin, implied Q4 revenue is roughly $2.82M. Compared to implied Q424 revenue of $2.69M (based on $0.9M EBITDA at 33.4% margin), Q4 revenue growth aggressively decelerated to under 5%. This is a massive red flag contradicting the headline narrative.
Gross Margin Squeeze
Cost of Goods Sold (COGS) grew 15.1% YoY to $6.98M, substantially outpacing the 11.8% revenue growth. Consequently, full-year gross margins compressed from 46.2% to 44.6%. The inability to pass input costs onto retail partners through pricing indicates a lack of pricing power in the grocery channel.
Fresh35°™ Cold Chain Innovation
The company's proprietary Fresh35°™ continuous cold-chain technology remains its primary differentiator. By delivering an 8-12 day shelf life without pasteurization or HPP (High Pressure Processing), Buda Juice provides grocery retailers with a turnkey, clean-label solution that avoids the operational complexities of in-store juicing.
Post-IPO Capitalization
With the January 2026 IPO completed, the company transitions from a cash-constrained operation (ending FY25 with just $1.8M in cash) to a capitalized growth entity. This capital is earmarked for national infrastructure expansion to scale the Ultra Fresh category.
Absence of Macro and Pricing Commentary
Despite clear margin pressures, management provided zero commentary on macroeconomic headwinds, grocery foot traffic trends, or supply chain inflation. Investors are left completely blind as to whether the COGS and SG&A spikes are due to structural company investments or unmitigated macro inflation.
Other KPIs
Accelerating wildly. SG&A jumped 28.8% YoY, far exceeding the 11.8% revenue growth. Even excluding a minor $0.1M IPO-readiness expense adjustment, operational overhead is stripping the company of its operating leverage and dragging net income into negative YoY territory.
Decelerating. FCF declined 9% YoY from $3.3M in FY24, primarily driven by lower cash from operations as accounts payable and other current liabilities shifted unfavorably. Capital expenditures remained incredibly light at just $0.3M for the year.
Key Questions
Q4 Revenue Deceleration
Based on your Q4 Adjusted EBITDA margins, implied Q4 top-line growth slowed to the mid-single digits. What drove this sharp deceleration at the end of the year, and has this trend continued into Q1 2026?
SG&A Run-Rate Post IPO
SG&A expenses grew nearly 30% in FY25. With the added burdens of operating as a public company, what is the expected structural SG&A run-rate for FY26?
Pricing Power and COGS
COGS grew 15% against 12% revenue growth, pressuring gross margins. Are you facing pushback from grocers on taking price to offset these higher production and cold-chain costs?
FY26 Guidance Timeline
Following the January IPO, when does management plan to issue formal FY26 forward guidance for revenue and Adjusted EBITDA?